BioWorld. Link to homepage.
BioWorld
BioWorld MedTech
BioWorld Asia
BioWorld Science
Data Snapshots
BioWorld
BioWorld MedTech
Infographics: Dynamic digital data analysis
Index insights
NME Digest
Special reports
Infographics: Dynamic digital data analysis
Trump administration impacts
Under threat: mRNA vaccine research
BioWorld at 35
Biopharma M&A scorecard
Bioworld 2025 review
BioWorld MedTech 2025 review
BioWorld Science 2025 review
Women's health
China's GLP-1 landscape
PFA re-energizes afib market
China CAR T
Alzheimer's disease
Coronavirus
More reports can be found here
BioWorld. Link to homepage.
Sign In
Sign Out
My Account
Subscribe
BioWorld - Thursday, January 15, 2026
See today's BioWorld
Home
» Threshold's Stock Slammed on Pancreatic Cancer Drug Data
To read the full story,
subscribe
or
sign in
.
Threshold's Stock Slammed on Pancreatic Cancer Drug Data
Sep. 18, 2012
By
Catherine Shaffer
Threshold Pharmaceuticals Inc. saw its shares fall 19.7 percent Monday, following release of an update to its Phase IIb trial of TH-302 in pancreatic cancer.
BioWorld
